Last Update 04 Mar 26

Fair value Decreased 12%

DCTH: Higher 2026 Spending Will Support Future Revenue Expansion Potential

Narrative Update on Delcath Systems

The analyst price target for Delcath Systems has been reduced by $3 to $27. Analysts point to updated FY26 sales guidance of at least $100M and significantly higher projected R&D and SG&A spending to support HEPZATO growth and label expansion as key factors behind the change.

Analyst Commentary

Recent research updates around Delcath Systems focus on how the company is setting expectations for HEPZATO and the spending required to support future growth. Price targets have moved in a relatively tight range, with analysts reacting to new sales guidance for FY26 and updated expense plans.

Bullish Takeaways

Bullish analysts view the new FY26 sales guidance of at least US$100M as a meaningful revenue marker that supports their valuation framework, even after modestly trimming price targets.
They see planned R&D and SG&A increases of nearly 90% and nearly 50% as an investment in HEPZATO label expansion and commercial reach, which they expect to underpin future revenue opportunities rather than simple cost pressure.
Earlier, bullish analysts pointed to Hepzato as a steady contributor, with quarter to quarter variability described as more predictable, which they see as helpful for modeling cash flow and funding potential new indications.
Some view the share price weakness following the FY26 guidance as driven by short term focus on higher expenses, and argue that the same spending could support execution on the HEPZATO growth plan that underlies their longer term thesis.

Bearish Takeaways

Bearish analysts highlight that the FY26 sales guidance of at least US$100M sits below the US$111M consensus estimate, which they see as a constraint on upside to prior valuation assumptions.
The planned near 90% increase in R&D and near 50% increase in SG&A are viewed by cautious investors as a risk to profitability and cash usage, particularly if label expansion or commercial scaling takes longer than expected.
Some see the need to raise and then lower price targets within a short window as a sign that earnings visibility may be limited, which can add uncertainty to both execution and valuation models.
There is concern that if HEPZATO growth or label expansion does not track internal expectations, the higher expense base set for 2026 could weigh on returns for longer than bulls currently assume.

What's in the News

Full results from the investigator-initiated CHOPIN Phase 2 trial in metastatic uveal melanoma using Delcath’s CHEMOSAT Hepatic Delivery System alone or with ipilimumab plus nivolumab were published in The Lancet Oncology, providing detailed efficacy and safety data on progression-free survival, overall survival, and response rates for the combination and monotherapy arms (The Lancet Oncology).
Subgroup analyses from the Phase 3 FOCUS study of HEPZATO KIT in unresectable metastatic uveal melanoma were published in the Journal of Cancer Research and Clinical Oncology, outlining how efficacy and safety outcomes varied by tumor burden, liver involvement, and LDH levels, and reinforcing the role of continued treatment through multiple cycles for some patients (Journal of Cancer Research and Clinical Oncology).
The company issued guidance for the fourth quarter of 2025, with HEPZATO KIT revenue expected to be approximately US$19.0 million and CHEMOSAT revenue approximately US$1.7 million, and for full year 2025, HEPZATO KIT revenue expected to be approximately US$78.8 million and CHEMOSAT revenue approximately US$6.4 million (Company guidance).
Between November 19, 2025 and December 31, 2025, Delcath Systems completed a share repurchase of 628,572 shares, representing 1.78% of shares, for US$6 million under its previously announced buyback program (Company buyback update).

Valuation Changes

Fair Value: trimmed from $24.33 to $21.33, a reduction of about 12%, reflecting updated model assumptions.
Discount Rate: edged up from 7.46% to 7.69%, a modest increase that slightly raises the hurdle rate applied to future cash flows.
Revenue Growth: reduced from 37.52% to 24.97%, indicating a materially lower growth assumption in the updated forecast.
Net Profit Margin: cut from 30.07% to 13.40%, a significant reset that implies a more conservative view on future profitability.
Future P/E: increased from 23.09x to 40.65x, suggesting a higher earnings multiple applied to the revised earnings outlook.

4 views

Key Takeaways

Growing demand for liver-focused cancer treatments and broader clinical trials are expanding Delcath's addressable markets and supporting long-term revenue growth.
Increased market access, hospital adoption, and European expansion are driving sustained volume growth and profitability despite some downward pricing pressure.
Heavy reliance on a single therapy, pricing pressures, operational complexities, rising expenses, and delayed market expansion heighten financial and competitive risks.

Catalysts

About Delcath Systems

An interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.What are the underlying business or industry changes driving this perspective?

Accelerated growth in HEPZATO and CHEMOSAT sales is being driven by increased incidence of liver and metastatic cancers due to demographic shifts, supporting long-term revenue expansion as Delcath addresses a growing clinical need.
Integration into the NDRA and 340B programs increases market access, particularly among large academic centers and underserved patient populations, which is likely to drive sustained volume growth and top-line revenue, partially offsetting the per-unit pricing reduction.
Expansion of clinical trials into major new indications (liver-dominant metastatic colorectal and breast cancer) opens larger addressable markets and positions Delcath for future revenue and earnings growth as patient populations multiply over the coming years.
Increased emphasis from payers and providers on innovative, organ-targeted and minimally invasive oncology solutions is supporting hospital adoption and utilization of Delcath's platform, contributing to higher gross margins and enhanced net profitability.
European and U.K. trial site expansion is expected to lay the groundwork for broader commercial uptake of CHEMOSAT, leveraging the growing global focus on rapid regulatory harmonization and wider acceptance of advanced oncology technologies, with potential positive impact on international revenues.

Delcath Systems Earnings and Revenue Growth

Delcath Systems Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Delcath Systems's revenue will grow by 37.5% annually over the next 3 years.
Analysts assume that profit margins will increase from 3.2% today to 30.1% in 3 years time.
Analysts expect earnings to reach $54.9 million (and earnings per share of $1.27) by about September 2028, up from $2.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $72.5 million in earnings, and the most bearish expecting $17.9 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 23.1x on those 2028 earnings, down from 170.8x today. This future PE is lower than the current PE for the US Medical Equipment industry at 28.6x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.46%, as per the Simply Wall St company report.

Delcath Systems Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Ongoing dependence on successful commercialization and clinical adoption of a single platform (HEPZATO/CHEMOSAT) increases revenue vulnerability if uptake stalls or if superior competing therapies-such as emerging systemic or non-invasive cancer treatments-diminish demand for invasive liver-directed therapies, risking future top-line growth and market share.
Heightened pricing pressures from payer programs (specifically, required 23.1% discounts for the 340B/NDRA programs which now affect roughly 50% of U.S. kits sold) create sustained downward pressure on average revenue per kit and may compromise long-term net margins and profitability, especially if future volume growth fails to fully offset these realized price cuts.
Complexity and unpredictability in activating new treatment sites-due to bureaucratic hurdles, the requirement for specialized perfusion services, and misalignment with standard care pathways at major academic centers-threaten to slow expansion, potentially leading to lower-than-anticipated revenue growth and underutilization of sales force investments.
Rapidly accelerating R&D and SG&A spend-R&D up over 140% year-over-year and projected further increases as new trials launch-could result in renewed net losses or negative cash flows should revenue growth disappoint, reducing investment flexibility and putting pressure on future earnings.
The long and uncertain timeline for clinical trial expansion into broader indications (CRC, breast cancer, new immunotherapy combinations) pushes realization of broader addressable markets and meaningful incremental revenues out to at least 2027–2030, exposing the company to considerable clinical, regulatory, and competitive risk over an extended period.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $24.333 for Delcath Systems based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $31.0, and the most bearish reporting a price target of just $21.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $182.7 million, earnings will come to $54.9 million, and it would be trading on a PE ratio of 23.1x, assuming you use a discount rate of 7.5%.
Given the current share price of $10.9, the analyst price target of $24.33 is 55.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Delcath Systems?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Expanded Clinical Trials And Program Integration Will Define Oncology's Future